Three-Dimensional Heart Segmentation and Absolute Quantitation of Cardiac I-metaiodobenzylguanidine Sympathetic Imaging Using SPECT/CT

Overview

Journal Ann Nucl Cardiol

Date 2023 Dec 7

PMID 38058582

Authors

Shintaro Saito

Kenichi Nakajima

Takayuki Shibutani

Hiroshi Wakabayashi

Hiroto Yoneyama

Takahiro Konishi

Hiroshi Mori

Aki Takata

Seigo Kinuya

Affiliations

Soon will be listed here.

Abstract

: A three-dimensional (3D) approach to absolute quantitation of I-metaiodobenzylguanidine (MIBG) sympathetic nerve imaging using single-photon emission tomography (SPECT) / computed tomography (CT) is not available. Therefore, we calculated absolute cardiac counts and standardized uptake values (SUVs) from images of 72 consecutive patients with cardiac and neurological diseases using I-MIBG SPECT/CT and compared them with conventional planar quantitation. We aimed to develop new methods for 3D heart segmentation and the quantitation of these diseases. : We manually segmented early and late SPECT/CT images of the heart in 3D, then calculated mean (SUV) and maximum (SUV) SUVs. We analyzed correlations between SUVs and planar heart-to-mediastinum ratios (HMRs), and between washout rates (WRs) derived from the SUVs and planar data. We also categorized WRs as normal or abnormal using linear regression lines determined by the relationship between SPECT/CT and planar WRs, and assessed agreement between them. : We calculated SUV and SUV from all early and late I-MIBG SPECT/CT images. Planar HMRs correlated with early and late SUV (R=0.59 and 0.73, respectively) and SUV (R=0.46 and 0.60, respectively; both p<0.0001). The SPECT/CT WRs determined based on SUV and SUV (R=0.79 and 0.45, p<0.0001) closely correlated with planar WRs. Agreement of high and low WRs between planar WRs and SPECT/CT WRs calculated using SUV and SUV reached 88.1% and 94.4% respectively. : We found that sympathetic nervous activity could be absolutely quantified in 3D from I-MIBG SPECT/CT images. Therefore, we propose a new method for quantifying sympathetic innervation on SPECT/CT images.

Citing Articles

Diagnostic Efficacy of Iodo-Metaiodobenzylguanidine SPECT/CT in Cardiac vs. Neurological Diseases: A Comparative Study of Arrhythmogenic Right Ventricular Cardiomyopathy and α-Synucleinopathies.

Hagen J, Scheifele M, Zacherl M, Katzdobler S, Bernhardt A, Brendel M Diagnostics (Basel). 2025; 15(1.

PMID: 39795552 PMC: 11720076. DOI: 10.3390/diagnostics15010024.

Iodine-123 Metaiodobenzylguanidine (I-123 MIBG) in Clinical Applications: A Comprehensive Review.

Chang M, Peng C, Chen C, Shih Y, Chen J, Tai Y Pharmaceuticals (Basel). 2025; 17(12.

PMID: 39770405 PMC: 11676292. DOI: 10.3390/ph17121563.

Absolute quantitation of sympathetic nerve activity using [I] metaiodobenzylguanidine SPECT-CT in neurology.

Saito S, Nakajima K, Komatsu J, Shibutani T, Wakabayashi H, Mori H EJNMMI Rep. 2024; 8(1):15.

PMID: 38822219 PMC: 11143090. DOI: 10.1186/s41824-024-00205-9.

References

McKeith I, Boeve B, Dickson D, Halliday G, Taylor J, Weintraub D . Diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB Consortium. Neurology. 2017; 89(1):88-100. PMC: 5496518. DOI: 10.1212/WNL.0000000000004058. View

Soman P, Travin M, Gerson M, Cullom S, Thompson R . I-123 MIBG Cardiac Imaging. J Nucl Cardiol. 2015; 22(4):677-85. DOI: 10.1007/s12350-015-0108-5. View

Nakajima K, Nakata T, Doi T, Tada H, Maruyama K . Machine learning-based risk model using I-metaiodobenzylguanidine to differentially predict modes of cardiac death in heart failure. J Nucl Cardiol. 2020; 29(1):190-201. PMC: 8873155. DOI: 10.1007/s12350-020-02173-6. View

Travin M, Henzlova M, van Eck-Smit B, Jain D, Carrio I, Folks R . Assessment of I-mIBG and Tc-tetrofosmin single-photon emission computed tomographic images for the prediction of arrhythmic events in patients with ischemic heart failure: Intermediate severity innervation defects are associated with higher.... J Nucl Cardiol. 2016; 24(2):377-391. DOI: 10.1007/s12350-015-0336-8. View

Nakajima K, Okuda K, Matsuo S, Wakabayashi H, Kinuya S . Is I-metaiodobenzylguanidine heart-to-mediastinum ratio dependent on age? From Japanese Society of Nuclear Medicine normal database. Ann Nucl Med. 2018; 32(3):175-181. PMC: 5852176. DOI: 10.1007/s12149-018-1231-6. View

Chen J, Garcia E, Galt J, Folks R, Carrio I . Optimized acquisition and processing protocols for I-123 cardiac SPECT imaging. J Nucl Cardiol. 2006; 13(2):251-60. DOI: 10.1007/BF02971250. View

Okuda K, Nakajima K, Hosoya T, Ishikawa T, Konishi T, Matsubara K . Semi-automated algorithm for calculating heart-to-mediastinum ratio in cardiac Iodine-123 MIBG imaging. J Nucl Cardiol. 2010; 18(1):82-9. DOI: 10.1007/s12350-010-9313-4. View

Dickson J, Armstrong I, Minguez Gabina P, Denis-Bacelar A, Krizsan A, Gear J . EANM practice guideline for quantitative SPECT-CT. Eur J Nucl Med Mol Imaging. 2022; 50(4):980-995. PMC: 9931838. DOI: 10.1007/s00259-022-06028-9. View

Verschure D, Nakajima K, Verberne H . Cardiac I-IBG Imaging in Heart Failure. Pharmaceuticals (Basel). 2022; 15(6). PMC: 9230638. DOI: 10.3390/ph15060656. View

10.

Nakajima K, Nakata T, Doi T, Kadokami T, Matsuo S, Konno T . Validation of 2-year 123I-meta-iodobenzylguanidine-based cardiac mortality risk model in chronic heart failure. Eur Heart J Cardiovasc Imaging. 2018; 19(7):749-756. PMC: 6012774. DOI: 10.1093/ehjci/jey016. View

11.

Bateman T, Ananthasubramaniam K, Berman D, Gerson M, Gropler R, Henzlova M . Reliability of the I-mIBG heart/mediastinum ratio: Results of a multicenter test-retest reproducibility study. J Nucl Cardiol. 2018; 26(5):1555-1565. DOI: 10.1007/s12350-017-1183-6. View

12.

Orimo S, Suzuki M, Inaba A, Mizusawa H . 123I-MIBG myocardial scintigraphy for differentiating Parkinson's disease from other neurodegenerative parkinsonism: a systematic review and meta-analysis. Parkinsonism Relat Disord. 2012; 18(5):494-500. DOI: 10.1016/j.parkreldis.2012.01.009. View

13.

Klene C, Jungen C, Okuda K, Kobayashi Y, Helberg A, Mester J . Influence of ROI definition on the heart-to-mediastinum ratio in planar I-MIBG imaging. J Nucl Cardiol. 2016; 25(1):208-216. DOI: 10.1007/s12350-016-0708-8. View

14.

Flotats A, Carrio I, Agostini D, Le Guludec D, Marcassa C, Schafers M . Proposal for standardization of 123I-metaiodobenzylguanidine (MIBG) cardiac sympathetic imaging by the EANM Cardiovascular Committee and the European Council of Nuclear Cardiology. Eur J Nucl Med Mol Imaging. 2010; 37(9):1802-12. DOI: 10.1007/s00259-010-1491-4. View

15.

Verschure D, Bongers V, Hagen P, Somsen G, van Eck-Smit B, Verberne H . Impact of a predefined mediastinal ROI on inter-observer variability of planar ¹²³I-MIBG heart-to-mediastinum ratio. J Nucl Cardiol. 2014; 21(3):605-13. DOI: 10.1007/s12350-014-9854-z. View

16.

Pellegrino T, Petretta M, De Luca S, Paolillo S, Boemio A, Carotenuto R . Observer reproducibility of results from a low-dose 123I-metaiodobenzylguanidine cardiac imaging protocol in patients with heart failure. Eur J Nucl Med Mol Imaging. 2013; 40(10):1549-57. DOI: 10.1007/s00259-013-2461-4. View

17.

Nakajima K, Scholte A, Nakata T, Dimitriu-Leen A, Chikamori T, Vitola J . Cardiac sympathetic nervous system imaging with I-meta-iodobenzylguanidine: Perspectives from Japan and Europe. J Nucl Cardiol. 2017; 24(3):952-960. DOI: 10.1007/s12350-017-0818-y. View

18.

Nakajima K, Nakata T, Yamada T, Yamashina S, Momose M, Kasama S . A prediction model for 5-year cardiac mortality in patients with chronic heart failure using ¹²³I-metaiodobenzylguanidine imaging. Eur J Nucl Med Mol Imaging. 2014; 41(9):1673-82. PMC: 4122818. DOI: 10.1007/s00259-014-2759-x. View

19.

Tilkemeier P, Bourque J, Doukky R, Sanghani R, Weinberg R . ASNC imaging guidelines for nuclear cardiology procedures : Standardized reporting of nuclear cardiology procedures. J Nucl Cardiol. 2017; 24(6):2064-2128. DOI: 10.1007/s12350-017-1057-y. View

20.

Nakajima K, Yamada M . (123)I-Meta-iodobenzylguanidine Sympathetic Imaging: Standardization and Application to Neurological Diseases. Chonnam Med J. 2016; 52(3):145-50. PMC: 5040763. DOI: 10.4068/cmj.2016.52.3.145. View